1 not yet recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow OT-101: new trials by email Literature Review of OT-101 trials Research Report on OT-101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition OT-101 - Malignant Pleural Mesothelioma | Phase 2 | Not yet recruiting | Oncotelic Inc. | 63 | 2025-06-01 | 2024-03-15 |
| A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer OT-101, mFOLFIRINOX - Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Oncotelic Inc. | 455 | 2024-05-01 | 2024-08-13 |
| A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects OT-101, Artemisinin, Placebo - COVID-19 | Phase 2 | Unknown | Oncotelic Inc. | 18 | 2021-04-01 | 2021-03-16 |
COVID-19 (1) · Mesothelioma, Malignant (1)
Oncotelic Inc. (3)
United States (2) · Brazil (1)
Vuong Trieu, PhD (1)